News about "EBITDA"

Lupin's US Business May Moderate After Strong Q1, Says Equirus Securities

Equirus Securities expects Lupin’s US business to moderate amid rising competition, while new launches and expanding chronic and international portfolios could support overall growth.

EBITDA | 14/08/2026 | By News Bureau

Merck Delivers Robust Q2 2026 Performance

Merck reported strong Q2 2026 results with 4.1 percent organic sales growth, higher EBITDA, upgraded full-year guidance and planned Bio-Techne acquisition.

EBITDA | 06/08/2026 | By News Bureau

Indoco Remedies Reports Improved Q1 FY27 Revenue and EBITDA

Indoco Remedies reported higher revenue and improved EBITDA in Q1 FY27, supported by the strong performance of its domestic formulations business and steady progress in international formulations and APIs.

EBITDA | 28/07/2026 | By News Bureau

Stada Eyes Autumn IPO as Sale Talks Stall and Market Conditions Improve

Stada and its owners are also considering alternative ownership options, including a potential sale. The company previously held talks with private equity firm CapVest, which would have valued Stada at around 10 billion euro including debt. Those discussions have since stalled, prompting a stronger push toward the IPO route.

EBITDA | 29/08/2025 | By Darshana |  151

Sai Life Sciences Eyes Global Expansion as Revenue Hits INR 1,115.1 Crore

The company reported a 15 percent increase in revenue and a 36 percent rise in net profit compared to the same period last year, driven by strong execution, expanding capacity, and deepening customer relationships.

EBITDA | 10/02/2025 | By Aishwarya |  1229

Zydus Reports Robust Growth in Q3 FY25 with a 17 Percent Increase in Revenue

Zydus Lifesciences recorded revenue from operations at INR 52,691 million, marking a 17 percent increase year-over-year.

EBITDA | 06/02/2025 | By Aishwarya |  1356

OneSource Achieves INR 3,926 Million Revenue in Q3FY25

OneSource demonstrated exceptional profitability with EBITDA reaching INR 1,432 million, an 85 percent increase compared to the previous quarter, resulting in a robust EBITDA margin of 36.5 percent, up by 1,334 basis points quarter-on-quarter.

EBITDA | 01/02/2025 | By Aishwarya |  878

Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25

The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.

EBITDA | 31/01/2025 | By Aishwarya |  1622

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

EBITDA | 29/10/2024 | By Aishwarya |  927

Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance

Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.

EBITDA | 23/05/2024 | By Aishwarya |  996